AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33929337 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Cardio [Nokia Withings]
Number of subjects: 153
Study 33929346 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory Volume Monitor (RVM)
Number of subjects: 40
Study 33929346 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory Volume Monitor (RVM) with patient calibration
Number of subjects: 40
Study 33929346 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory Volume Monitor (RVM) without patient calibration
Number of subjects: 40
Study 33929361 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium present on a given day
Number of subjects: 1040
Study 33929361 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoactive delirium
Number of subjects: 1040
Study 33929361 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperactive delirium
Number of subjects: 1040
Study 33929361 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium presence among hospital survivors
Number of subjects: 1040
Study 33929361 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium duration among hospital survivors
Number of subjects: 1040
Study 33929377 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk assessment in the emergency department for very-low-risk patients (Glasgow-Blatchford score = 0-1)
Number of subjects: 0
Study 33929377 — intervention group
Group type: EXPERIMENTAL
Intervention: Red blood cell transfusion at a threshold of 7 g/dL
Number of subjects: 0
Study 33929377 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin infusion before endoscopy
Number of subjects: 0
Study 33929377 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopy within 24 hours after presentation
Number of subjects: 0
Study 33929377 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic therapy for ulcers with active spurting or oozing and for nonbleeding visible vessels
Number of subjects: 0
Study 33929377 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic therapy with bipolar electrocoagulation, heater probe, and absolute ethanol injection
Number of subjects: 0
Study 33929377 — intervention group
Group type: EXPERIMENTAL
Intervention: Clips, argon plasma coagulation, and soft monopolar electrocoagulation
Number of subjects: 0
Study 33929377 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemostatic powder spray TC-325
Number of subjects: 0
Study 33929377 — intervention group
Group type: EXPERIMENTAL
Intervention: Over-the-scope clips for recurrent ulcer bleeding after previous successful hemostasis
Number of subjects: 0
Study 33929377 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose proton pump inhibitor therapy continuously or intermittently for 3 days, followed by twice-daily oral proton pump inhibitor for the first 2 weeks after endoscopy
Number of subjects: 0
Study 33929377 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat endoscopy for recurrent bleeding
Number of subjects: 0
Study 33929377 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter embolization if endoscopic therapy fails
Number of subjects: 0
Study 33929394 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 Inhibitor
Number of subjects: 0
Study 33929496 — intervention group
Group type: EXPERIMENTAL
Intervention: Gained insurance
Number of subjects: 126699
Study 33929496 — intervention group
Group type: EXPERIMENTAL
Intervention: Uninsured patients
Number of subjects: 126699
Study 33929496 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-ACA diagnosis
Number of subjects: 126699
Study 33929496 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 126699
Study 33929641 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic cardiac output monitor (USCOM)
Number of subjects: 127
Study 33929641 — intervention group
Group type: COMPARATOR
Intervention: Echocardiography
Number of subjects: 127
Study 33929686 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran (Cohort A)
Number of subjects: 9472
Study 33929686 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran (Cohort B)
Number of subjects: 9472
Study 33929686 — intervention group
Group type: COMPARATOR
Intervention: Dabigatran and VKAs (Cohort B)
Number of subjects: 9472
Study 33929686 — intervention group
Group type: COMPARATOR
Intervention: VKAs (Cohort B)
Number of subjects: 9472
Study 33929874 — intervention group
Group type: EXPERIMENTAL
Intervention: BKV-specific cytotoxic T lymphocytes (CTLs) infusion
Number of subjects: 59
Study 33929895 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG) 10 mg/kg on days 1 and 8 of 21-day cycles
Number of subjects: 113
Study 33929895 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG)
Number of subjects: 113
Study 33929935 — intervention group
Group type: EXPERIMENTAL
Intervention: Metagenomic next-generation sequencing
Number of subjects: 816
Study 33930223 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-tablet combination of sofosbuvir (400 mg) and daclatasvir (30, 60, or 90 mg) for 12 or 24 weeks
Number of subjects: 233
Study 33930518 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenestrated endovascular aneurysm repair (FEVAR)
Number of subjects: 124
Study 33931404 — intervention group
Group type: EXPERIMENTAL
Intervention: Milder prolonged hypoglycemia (2.8 mmol/L for 1 hour) in control subjects
Number of subjects: 63
Study 33931404 — intervention group
Group type: COMPARATOR
Intervention: Severe transient hypoglycemia (2.0 mmol/L transiently) in control subjects
Number of subjects: 63
Study 33931404 — intervention group
Group type: EXPERIMENTAL
Intervention: Milder prolonged hypoglycemia in T2D subjects
Number of subjects: 63
Study 33931404 — intervention group
Group type: COMPARATOR
Intervention: Severe transient hypoglycemia in T2D subjects
Number of subjects: 63
Study 33931857 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitopertin, a glycine transport inhibitor, administered orally, dosage and duration not available.
Number of subjects: 0
Study 33931857 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified.
Number of subjects: 0
Study 33931953 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg allopurinol
Number of subjects: 0
Study 33931953 — intervention group
Group type: COMPARATOR
Intervention: Clinical inhibitors of BCRP
Number of subjects: 0
Study 33931973 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 0
Study 33932113 — intervention group
Group type: EXPERIMENTAL
Intervention: LACE index (length of stay, acuity, Charlson co-morbidities, emergent visits)
Number of subjects: 1985
Study 33932113 — intervention group
Group type: EXPERIMENTAL
Intervention: LE index (length of stay and emergent visits)
Number of subjects: 1985
Study 33932130 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib 150 mg twice daily
Number of subjects: 0
Study 33932130 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 3 mg
Number of subjects: 0
Study 33932130 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin 10 mg
Number of subjects: 0
Study 33932223 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec (± prandial insulin)
Number of subjects: 626
Study 33932223 — intervention group
Group type: COMPARATOR
Intervention: Other basal insulins (± prandial insulin)
Number of subjects: 626
Study 33932502 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0
Study 33933036 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory oxygen therapy
Number of subjects: 42
Study 33933036 — intervention group
Group type: COMPARATOR
Intervention: Control group (age- and gender-matched from the general population)
Number of subjects: 42
Study 33933087 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater depressive symptoms during pregnancy (β ± SE = 0.03 ± 0.01, p < .01)
Number of subjects: 0
Study 33933087 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher stress during pregnancy (β ± SE = 0.03 ± 0.01, p < .01)
Number of subjects: 0
Study 33933087 — intervention group
Group type: EXPERIMENTAL
Intervention: Worse sleep quality during pregnancy (β ± SE = 0.03 ± 0.01, p = 0.03)
Number of subjects: 0
Study 33933087 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater depressive symptoms during pregnancy (OR = 1.08, 95% CI: 1.02, 1.14, p = .01)
Number of subjects: 0
Study 33933087 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher stress during pregnancy (OR = 1.09, 95% CI: 1.04, 1.14, p < .01)
Number of subjects: 0
Study 33933087 — intervention group
Group type: EXPERIMENTAL
Intervention: Worse sleep quality during pregnancy (OR = 1.09, 95% CI: 1.00, 1.18, p = .04)
Number of subjects: 0
Study 33933087 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater depressive symptoms during pregnancy (β ± SE = 0.06 ± 0.02, p < .01)
Number of subjects: 0
Study 33933087 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher stress during pregnancy (β ± SE = 0.04 ± 0.01, p < .01)
Number of subjects: 0
Study 33933087 — intervention group
Group type: EXPERIMENTAL
Intervention: Worse sleep quality during pregnancy (β ± SE = 0.11 ± 0.03, p < .01)
Number of subjects: 0
Study 33933087 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased depressive symptoms from pregnancy to postpartum (β ± SE = 1.17 ± 0.57, p = 0.01)
Number of subjects: 0
Study 33933087 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased depressive symptoms from pregnancy to postpartum (0.88 ± 0.33, p = 0.01)
Number of subjects: 0
Study 33933087 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased stress from pregnancy to postpartum (1.71 ± 0.76, p = 0.02)
Number of subjects: 0
Study 33933118 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiotherapy (RT)
Number of subjects: 35
Study 33933408 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary Valve Replacement (PVR)
Number of subjects: 165
Study 33933408 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary Valve Replacement (PVR) before ICD implantation
Number of subjects: 165
Study 33933412 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Field Ablation (PFA)
Number of subjects: 121
Study 33933412 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Field Ablation (PFA) with optimized biphasic energy
Number of subjects: 121
Study 33933689 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to Daily Occupational Performance (CO-OP) intervention, 14 individual sessions
Number of subjects: 2
Study 33933689 — intervention group
Group type: COMPARATOR
Intervention: Control goal (not trained)
Number of subjects: 2
Study 33933719 — intervention group
Group type: EXPERIMENTAL
Intervention: First-episode antipsychotic-naïve patients with schizophrenia
Number of subjects: 36
Study 33933719 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 36
Study 33933719 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined analysis of patients and controls
Number of subjects: 36
Study 33933719 — intervention group
Group type: EXPERIMENTAL
Intervention: First-episode antipsychotic-naïve patients with schizophrenia and Healthy controls
Number of subjects: 36
Study 33933733 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fiber intake
Number of subjects: 50
Study 33933733 — intervention group
Group type: EXPERIMENTAL
Intervention: Total dietary fiber, insoluble, soluble dietary fiber, and galacto-oligosaccharide intakes
Number of subjects: 50
Study 33933733 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble dietary fiber intake
Number of subjects: 50
Study 33933895 — intervention group
Group type: EXPERIMENTAL
Intervention: HFRT-CHT using IMRT technique (51 Gy in 17 fractions or 40 Gy in 10 fractions followed by a boost of 15 Gy in 5 fractions or 28 Gy in 7 fractions)
Number of subjects: 58
Study 33933895 — intervention group
Group type: EXPERIMENTAL
Intervention: HFRT-CHT using IMRT technique
Number of subjects: 58
Study 33933925 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionated radiation therapy (CFRT)
Number of subjects: 0
Study 33933925 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmastectomy hypofractionated radiation therapy (HFRT)
Number of subjects: 0
Study 33934110 — intervention group
Group type: EXPERIMENTAL
Intervention: Pittsburgh Compound-B (PiB) imaging
Number of subjects: 0
Study 33934200 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline
Number of subjects: 0
Study 33934200 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine
Number of subjects: 0
Study 33934200 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaine
Number of subjects: 0
Study 33934200 — intervention group
Group type: EXPERIMENTAL
Intervention: γ-butyrobetaine (γ-BB)
Number of subjects: 0
Study 33934200 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,3-Dimethyl-1-butanol (DMB)
Number of subjects: 0
Study 33934351 — intervention group
Group type: EXPERIMENTAL
Intervention: MIV-mono (mivebresib at doses of 1.5, 2.0, or 2.5 mg)
Number of subjects: 44
Study 33934351 — intervention group
Group type: EXPERIMENTAL
Intervention: MIV-Ven (mivebresib in combination with venetoclax at doses of 400 or 800 mg)
Number of subjects: 44
Study 33934706 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergic conjunctivitis (AC) group
Number of subjects: 50
Study 33934709 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid group (web-based decision aid created by Healthwise)
Number of subjects: 300
Study 33934709 — intervention group
Group type: COMPARATOR
Intervention: Control group (information about driving without evidence-based elements)
Number of subjects: 300
Study 33934709 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid group
Number of subjects: 300
Study 33934709 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 300
Study 33934715 — intervention group
Group type: EXPERIMENTAL
Intervention: Essen-ICH-score
Number of subjects: 0
Study 33934715 — intervention group
Group type: EXPERIMENTAL
Intervention: max-ICH score
Number of subjects: 0
Study 33934715 — intervention group
Group type: COMPARATOR
Intervention: Various prediction scores
Number of subjects: 0
Study 33935163 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-acquired pneumonia-macrophage activation-like syndrome (n = 15; 9.8%)
Number of subjects: 153
Study 33935163 — intervention group
Group type: COMPARATOR
Intervention: Community-acquired pneumonia-control (n = 138; 90.2%)
Number of subjects: 153
Study 33935163 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-acquired pneumonia-macrophage activation-like syndrome (n = 15)
Number of subjects: 153
Study 33935163 — intervention group
Group type: COMPARATOR
Intervention: Community-acquired pneumonia-control (n = 138)
Number of subjects: 153
Study 33935163 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis excluding patients with hematologic malignancies (n = 141)
Number of subjects: 153
Study 33935214 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoneurological symptoms in Study 1
Number of subjects: 0
Study 33935214 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoneurological symptoms in Study 2
Number of subjects: 0
Study 33935214 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoneurological symptoms mediating stressors and maternal functions in Study 2
Number of subjects: 0
Study 33935282 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week supervised combined aerobic resistance-exercise program
Number of subjects: 1983
Study 33935282 — intervention group
Group type: COMPARATOR
Intervention: Physical activity level (less active vs more active)
Number of subjects: 1983
Study 33935282 — intervention group
Group type: COMPARATOR
Intervention: Exercise training
Number of subjects: 1983
Study 33935738 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33935773 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 0
Study 33935825 — intervention group
Group type: EXPERIMENTAL
Intervention: Modular Psychotherapy
Number of subjects: 0
Study 33935825 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33935935 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Orthostatic Exercise by Head-Up Tilt With Stepping
Number of subjects: 0
Study 33935935 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 0
Study 33935966 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibin B
Number of subjects: 2524
Study 33935966 — intervention group
Group type: COMPARATOR
Intervention: FSH
Number of subjects: 2524
Study 33936110 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated TNFα (median (IQR): 8.2 (6.4-9.8) pg/ml)
Number of subjects: 783
Study 33936110 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated IL-1β (0.21 (0.1-0.4) pg/ml)
Number of subjects: 783
Study 33936809 — intervention group
Group type: EXPERIMENTAL
Intervention: Fovea-sparing ILM peeling technique
Number of subjects: 5
Study 33936953 — intervention group
Group type: EXPERIMENTAL
Intervention: NO-FEAR Airlines with navigable images
Number of subjects: 60
Study 33936953 — intervention group
Group type: EXPERIMENTAL
Intervention: NO-FEAR Airlines with still images
Number of subjects: 60
Study 33936953 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 60
Study 33937527 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropin-Releasing Hormone Agonists
Number of subjects: 0
Study 33937603 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33937611 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy intervention for coping with breast cancer treatment
Number of subjects: 0
Study 33937611 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33937624 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of somatic mutations of estrogen receptor alpha
Number of subjects: 3217
Study 33937906 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33937953 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg co-administered with modafinil 400 mg/day
Number of subjects: 16
Study 33937953 — intervention group
Group type: COMPARATOR
Intervention: Lorlatinib 100 mg alone
Number of subjects: 16
Study 33937954 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib (10-200 mg orally once daily and twice-daily doses of 35, 75, and 100 mg in continuous 21-day cycles for phase I; 100 mg once daily in continuous 21-day cycles for phase II)
Number of subjects: 329
Study 33937954 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Number of subjects: 329
Study 33938407 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33938716 — intervention group
Group type: EXPERIMENTAL
Intervention: Host response bacterial/viral test
Number of subjects: 623
Study 33938716 — intervention group
Group type: COMPARATOR
Intervention: Procalcitonin
Number of subjects: 623
Study 33938805 — intervention group
Group type: EXPERIMENTAL
Intervention: Nam Nalavazhvu intervention (norm-centric behavior change intervention)
Number of subjects: 76
Study 33938805 — intervention group
Group type: COMPARATOR
Intervention: Control group (counterfactuals)
Number of subjects: 76
Study 33939006 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow diameter implants in T2DM patients (HbA1C > 6.5%)
Number of subjects: 32
Study 33939006 — intervention group
Group type: COMPARATOR
Intervention: Narrow diameter implants in normo-glycemic patients (HbA1C < 6.0%)
Number of subjects: 32
Study 33939006 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow diameter implants in both groups
Number of subjects: 32
Study 33939067 — intervention group
Group type: EXPERIMENTAL
Intervention: DSP-7888 administered intradermally (ID) at doses of 3.5 mg, 10.5 mg, and 17.5 mg.
Number of subjects: 24
Study 33939067 — intervention group
Group type: EXPERIMENTAL
Intervention: DSP-7888 administered subcutaneously (SC) at doses of 3.5 mg and 10.5 mg.
Number of subjects: 24
Study 33939068 — intervention group
Group type: EXPERIMENTAL
Intervention: Savolitinib monotherapy 400 mg once daily (qd)
Number of subjects: 29
Study 33939068 — intervention group
Group type: EXPERIMENTAL
Intervention: Savolitinib monotherapy 600 mg qd
Number of subjects: 29
Study 33939068 — intervention group
Group type: EXPERIMENTAL
Intervention: Savolitinib 400 mg qd + Osimertinib 80 mg
Number of subjects: 29
Study 33939068 — intervention group
Group type: EXPERIMENTAL
Intervention: Savolitinib 300 mg qd + Osimertinib 80 mg
Number of subjects: 29
Study 33939068 — intervention group
Group type: EXPERIMENTAL
Intervention: Savolitinib 600 mg qd + Osimertinib 80 mg
Number of subjects: 29
Study 33939124 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV infection
Number of subjects: 0
Study 33939124 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk HPV infections
Number of subjects: 0
Study 33939158 — intervention group
Group type: EXPERIMENTAL
Intervention: tiotropium/olodaterol Respimat
Number of subjects: 0
Study 33939529 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-adjusted D-Dimer cutoff
Number of subjects: 0
Study 33939529 — intervention group
Group type: COMPARATOR
Intervention: Standard D-Dimer cutoff
Number of subjects: 0
Study 33939604 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary intravascular lithotripsy (IVL)
Number of subjects: 628
Study 33940581 — intervention group
Group type: EXPERIMENTAL
Intervention: Telotristat ethyl (250 or 500 mg thrice daily)
Number of subjects: 124
Study 33940581 — intervention group
Group type: EXPERIMENTAL
Intervention: Telotristat ethyl
Number of subjects: 124
Study 33940642 — intervention group
Group type: COMPARATOR
Intervention: Cross-sectional fundal height measurement ≤ -3 cm at visit 3 (mean: 32.0 ± 1.6 weeks)
Number of subjects: 1939
Study 33940642 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of longitudinal fundal height
Number of subjects: 1939
Study 33941089 — intervention group
Group type: EXPERIMENTAL
Intervention: Stakeholder-engaged process for refining the design of a clinical trial in home hospice
Number of subjects: 9
Study 33941089 — intervention group
Group type: EXPERIMENTAL
Intervention: Stakeholder engagement process
Number of subjects: 9
Study 33941111 — intervention group
Group type: EXPERIMENTAL
Intervention: Kilovoltage Intrafraction Monitoring (KIM) guidance
Number of subjects: 46
Study 33941111 — intervention group
Group type: COMPARATOR
Intervention: Stereotactic Ablative Body Radiotherapy (SABR)
Number of subjects: 46
Study 33941281 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-9
Number of subjects: 0
Study 33941281 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-9-producing CD4(+) T cells
Number of subjects: 0
Study 33941281 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-9 and D-lactate levels
Number of subjects: 0